Orchestra BioMed Holdings annual free cash flow
2022
2023
2024
2025
Orchestra BioMed Holdings Free Cash Flow (FCF) History (OBIO)
Orchestra BioMed Holdings reported −$49.5M in free cash flow for fiscal 2025, an increase of $1.4M from the previous fiscal year, with a free cash flow margin of −147.70%.
View full Orchestra BioMed Holdings company overviewOrchestra BioMed Holdings free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$49.5M | $1.4M | — | −147.70% |
| 2024 | 2024-12-31 | −$50.8M | −$4.6M | — | −1927.48% |
| 2023 | 2023-12-31 | −$46.2M | −$16.3M | — | −1674.09% |
| 2022 | 2022-12-31 | −$29.9M | — | — | −845.74% |
Orchestra BioMed Holdings quarterly free cash flow
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$19.6M | −$4.0M | — | −22256.82% |
| Q1 2026 | 2026-03-31 | −$22.4M | −$5.6M | — | −20320.00% |
| Q4 2025 | 2025-12-31 | −$2.3M | $11.3M | — | −7.45% |
| Q3 2025 | 2025-09-30 | −$14.9M | −$1.1M | — | −1725.90% |
| Q2 2025 | 2025-06-30 | −$15.6M | −$5.2M | — | −1861.36% |
| Q1 2025 | 2025-03-31 | −$16.7M | −$3.6M | — | −1927.19% |
| Q4 2024 | 2024-12-31 | −$13.6M | −$2.7M | — | −5392.89% |
| Q3 2024 | 2024-09-30 | −$13.8M | −$3.5M | — | −1394.93% |
| Q2 2024 | 2024-06-30 | −$10.3M | $204,000 | — | −1325.58% |
| Q1 2024 | 2024-03-31 | −$13.1M | $1.3M | — | −2116.45% |
| Q4 2023 | 2023-12-31 | −$11.0M | −$2.2M | — | −4189.69% |
| Q3 2023 | 2023-09-30 | −$10.3M | −$2.8M | — | −2458.47% |
| Q2 2023 | 2023-06-30 | −$10.5M | −$2.3M | — | −1149.40% |
| Q1 2023 | 2023-03-31 | −$14.4M | −$9.0M | — | −1238.49% |
| Q4 2022 | 2022-12-31 | −$8.8M | — | — | −797.64% |
| Q3 2022 | 2022-09-30 | −$7.5M | — | — | −643.16% |
| Q2 2022 | 2022-06-30 | −$8.2M | — | — | −2052.62% |
| Q1 2022 | 2022-03-31 | −$5.4M | — | — | −620.21% |
Orchestra BioMed Holdings free cash flow growth trends
Orchestra BioMed Holdings's latest reported quarter, Q2 2026, generated −$19.6M in free cash flow, a decrease of $4.0M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Orchestra BioMed Holdings filings at SEC.gov ↗